


TPMS Patient

Patient Name: [REDACTED] [REDACTED]

Patient ID: [REDACTED]

Treatment Plan: [REDACTED]



III THERAPY REJECTED !!!

This therapy was rejected for the following reason(s) Additional information about the therapy is provided but this therapy is NOT advisable

- Viramune (nevirapine/NVP) Resistance Advisory: According to the last genotype data entered, the patient's virus currently has mutation(s) which is/are associated with resistance to Viramune. F1ResE, RejectionS4
- Resistance Advisory: According to the last genotype data entered, the patient's virus currently has the following mutations; M184V [RT]. The genotype test displays evidence of the M184V/M184I mutation which is associated with resistance to 3TC . However, this mutant has increased sensitivity to the antiRetroviral activity of AZT and ADV so an AZT/3TC or AZT/ADV combination is still useable. Therefore combinations which contain AZT/3TC and AZT/ADV are shown as therapy options although these therapies have been ranked down +5 in favor of three drug combinations with no resistant mutants. F1MutB, RejectionS1
- Epivir and Viramune Resistance Advisory: The patient's last phenotypic assay demonstrates phenotypic resistance to Epivir and Viramune, therefore, therapies containing Epivir and Viramune are not recommended at this time. F1ResC, RejectionS2

F16. 123



- NVP Δ: Drug Interaction Alert: Patient is currently taking rifabutin and there is insufficient data to assess whether dose adjustments are necessary. These drugs



TPMS